Filing Flows › Artivion (AORT) › Q3 2026 › vs Q2 2026
Artivion (AORT) Q3 2026 vs Q2 2026 (quarter over quarter)
Artivion's revenue fell $2.0M (-2%) from $126M in Q2 2026 to $124M in Q3 2026. The biggest changes: Products −$1.7M (-2%); Preservation services −$222K (-0.9%).
Artivion, Q3 2026: revenue $124M (+9% year over year), operating margin 2.4%, net loss $7.9M, operating cash flow −$4.6M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Aortic stent grafts | $44.3M | $46.4M | −$2.1M | -5% |
| On-X | $30.3M | $30.5M | −$189K | -0.6% |
| Surgical sealants | $18.9M | $19.3M | −$341K | -2% |
| Other | $4.6M | $3.7M | $921K | +25% |
| Products | $98.2M | $99.9M | −$1.7M | -2% |
| Preservation services | $25.6M | $25.9M | −$222K | -0.9% |
| Revenue | $124M | $126M | −$2.0M | -2% |
| Net loss | $7.9M | $13.5M | −$5.6M | -41% |
| Costs & expenses | $132M | $139M | −$7.6M | -5% |
| Operating costs | $121M | $134M | −$13.3M | -10% |
| Interest & other, net | $8.9M | $3.3M | $5.5M | +166% |
| Income tax | $2.0M | $1.8M | $195K | +11% |
| Cost of revenue | $47.8M | $45.2M | $2.6M | +6% |
| Research & development | $9.8M | $9.1M | $753K | +8% |
| SG&A | $63.2M | $79.8M | −$16.6M | -21% |
| Operating cash sources | $18.1M | $16.2M | $1.9M | +12% |
| Depreciation & amortization | $7.3M | $6.7M | $596K | +9% |
| Share-based compensation | $6.2M | $8.2M | −$1.9M | -24% |
| Cash used in operations | $4.6M | $1.3M | $3.3M | +260% |
| Net loss absorbed | $7.9M | $13.5M | −$5.6M | -41% |
| Working capital & other | $10.2M | $2.7M | $7.5M | +282% |
Questions
How much did Artivion's revenue grow quarter over quarter in Q3 2026?
Artivion's revenue fell $2.0M (-2%) from $126M in Q2 2026 to $124M in Q3 2026.
What drove Artivion's revenue change in Q3 2026?
Products −$1.7M (-2%); Preservation services −$222K (-0.9%).